AI Science Tracker

Mila – Quebec AI Institute

1 discovery from 2024

Discoveries

LAMBDAZERO generates an experimentally active soluble epoxide hydrolase inhibitor scaffold

The LAMBDAZERO generative active-learning workflow searched for synthesizable soluble epoxide hydrolase (sEH/EPHX2) inhibitors and produced a quinazoline scaffold absent from the authors' comparison set of known sEH inhibitors. A synthesized analog, UM0152893, inhibited sEH in vitro with sub-micromolar potency.

Technology: LAMBDAZERO generative active learning with deep reinforcement learning and docking

Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Preprint
  • Test type: direct test
  • Tested: The LAMBDAZERO generative active-learning workflow searched for synthesizable soluble epoxide hydrolase (sEH/EPHX2) inhibitors and produced a quinazoline scaffold absent from the authors' comparison set of known sEH inhibitors.
  • Still unknown: This is a workshop paper/preprint rather than a clinical study. The reported lead is a biochemical inhibitor of purified sEH; no cellular, animal, safety or therapeutic outcome is established. The authors report 24/35 synthesized analogs active in vitro with potency spanning roughly 90 μM to 0.4 μM; one best lead is sub-micromolar.
  • AI role: The generative model searched molecular space using docking, synthesizability and drug-likeness constraints and proposed the scaffold; researchers synthesized analogs and measured enzyme inhibition in biochemical assays.

Evidence sources: https://arxiv.org/abs/2405.01616

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.